NewBiologix SA launched as a technology innovation company developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The launch also includes the completion of a custom built 19,000 square-foot facility designed specifically for cell and gene therapy development.
The company’s DNA-based platform is being developed to address key manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to produce advanced therapy medicinal products (ATMPs).
